1 000 patienter med prostatakræft, 445 patienter med mavekræft og 897 patienter med kræft i hoved - og halsregionen.
Docetaxel Winthrop has been studied in a total of around 3,000 breast cancer patients, around 1,900 lung cancer patients, around 1,000 prostate cancer patients, 445 stomach cancer patients and 897 in head and neck cancer patients.